Efficacy of three drugs agomelatine, bupropion and sertraline in the treatment of major depressive disorder

Comparison of the effectiveness of three drugs agomelatine, bupropion and sertraline in the treatment of non psychotic major depressive disorder: A randomized double blind clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190525043700N4

Enrollment

Registered

2021-10-25

Start date

2021-10-23

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major depressive disorder. Major depressive disorder, single episode, mild

Interventions

Intervention 1: Intervention group1:Patients in the agomelatine group (Tadbir Kalay Jam Company) will initially receive 25 mg of the drug daily at bedtime for two weeks, and patients who do not show i

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age 20-60 years Major Depressive Disorder (Based on the diagnosis of a psychiatrist and a psychiatric assistant with a structured clinical interview based on the DSM-5)

Exclusion criteria

Exclusion criteria: Drug abuse Hypothyroidism Severe anemia Pregnancy and lactation Epilepsy Mental retardation

Design outcomes

Primary

Measure	Time frame
Patient´s depressive condition. Timepoint: Before the intervention (first visit), end of the second week (second visit), end of the fourth week (third visit), end of the eighth week (fourth visit). Method of measurement: Hamilton Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRomina Hamzehpour

Babol University of Medical Sciences

r.hamzehpour@mubabol.ac.ir+98 11 3219 9595

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026